ArticleQJM : monthly journal of the Association of Physicians2026
Increased risk of uveitis and optic neuritis after herpes zoster reactivation in COVID-19: a TriNetX database study.
Article in QJM : monthly journal of the Association of Physicians, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-COVID varicella-zoster virus reactivation: lowering the immunological threshold for latency breakdown.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHerpes zoster (HZ) reactivation following COVID-19 suggests immune dysregulation, posing a risk for long-term neuro-ophthalmic sequelae.
aimThis study investigates the relationship between post-COVID HZ and the subsequent hazard of uveitis and optic neuritis.
designThis retrospective analysis used the TriNetX Research Network, following patients for 3 years.
methodsPropensity score matching (PSM) was performed on COVID-19 survivors, comparing the HZ-exposed group (n = 11 172) against a matched HZ-unexposed control group (n = 11 173). Cox proportional hazards models calculated the 3-year Hazard Ratios (HRs) for incident uveitis and optic neuritis.
resultsPost-COVID-HZ reactivation was associated with a significantly elevated and persistent risk of both outcomes. HZ was consistently related to a 3.06-fold increase in the hazard of uveitis (HR = 3.06; 95% CI, 2.56-3.65; P < 0.001) and a 2.10-fold increase in the hazard of optic neuritis (HR = 2.10; 95% CI, 1.62-2.71; P < 0.001). The relationships remained significant across sensitivity analyses, and the risk remained high even in the vaccinated subgroup.
conclusionsHZ reactivation after COVID-19 is related to a higher instantaneous risk of subsequent uveitis and optic neuritis, even among immunocompetent individuals. HZ may serve as a clinical marker for neuro-immune injury, supporting the consideration of targeted ophthalmic surveillance and timely antiviral intervention to prevent vision loss.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.